As China's first company to achieve industrial-scale production of HMO components LNT (lacto-N-tetraose) and LNnT (lacto-N-neotetraose), we now boast fermentation yields more than double those of international competitors.
In May 2024, China's National Health Commission (NHC) initiated a public consultation regarding LNnT (lacto-N-neotetraose) as a novel food ingredient, followed by a similar consultation for LNT (lacto-N-tetraose) in June. These milestone regulatory developments mark a pivot advancement for domestic synthetic biology enterprises entering the infant formula ingredients sector.
